CROs and CDMOs are Still Selling Fast

This past week Permira, a global investment firm based in the United Kingdom, spent $2.4 billion for Cambrex Corporation (NYSE: CBM). Cambrex is a premier contract development and manufacturing organization (CDMO) in the small molecule space and provides drug substance, drug product and analytical services across the entire drug lifecycle. The $2.4 billion purchase price includes the company’s […]

Will Catalent’s Deal Launch the Next Wave of CRO M&A?

Contract research organizations (CROs), like contract development and manufacturing organizations (CDMOs), have been popular targets for private equity firms and strategic buyers for years. The deals seem to come in waves, and the healthcare M&A market may be in for a tsunami this year. In 2013, some 20 transactions for CRO/CDMO targets were announced, with […]

MedAssets Acquired and Split Up

Pamplona Capital Management, a New York-based investment group, announced its acquisition of MedAssets, Inc. (NASDAQ: MDAS) for $2.7 billion. MedAssets provides technology-enabled products and services for hospitals, health systems, non-acute healthcare providers, payers and other service providers. The price of $2.7 billion represents $31.35 per share. Pamplona already has an agreement in place to divest […]